BMI View: Given the small pharmaceutical market size coupled with the low per-capita pharmaceutical and healthcare spending, it is unlikely that Cambodia will present much opportunities over the medium term, although inexpensive generic drug players from countries such as India and Pakistan will benefit from this low expenditure market. We stress that extensive bureaucracy, rampant corruption and counterfeiting of pharmaceutical products remain as key threat in boosting healthcare provision. Headline Expenditure Projections ? Pharmaceuticals: KHR721.1bn (US$170mn) in 2012 to KHR789.3bn (US$190mn) in 2013; +9.5% in local currency terms and +8.2% in US dollar terms. Forecast broadly in line with Q313. …
Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=117417.
Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/cambodia-and-laos-pharmaceuticals-and-healthcare-report-q4-2013-market-report.html.
No comments:
Post a Comment